PRNewswire/ – BioAtla, LLC, a global biotechnology company focused on the development of Conditionally Active Biologic antibody therapeutics, today announced the appointment of Eric L. Sievers.
“Dr. Sievers’ experience and proven capabilities in leading the clinical development of innovative oncology products greatly enhances BioAtla’s ability to design, implement, and execute clinical programs evolving from our CAB platform that uniquely yields tumor-targeting antibodies with high safety,” said Jay M. Short.
Sievers joins BioAtla with over 25 years of clinical and translational biomedical research experience in multiple settings, including biotechnology industry, hospital- and clinic-based clinical practice and academics.
During his nine years at Seattle Genetics, he was closely involved with the development and regulatory approval of ADCETRIS, an ADC. Serving in multiple roles of increasing leadership responsibility, he led the Seattle Genetics clinical team and Takeda development partner to design, initiate and enroll four randomized Phase 3 registration trials for ADCETRIS that each ultimately resulted in new indications approved by the FDA. Dr. Sievers has managed clinical development efforts from Phase 1 to Phase 3 clinical trials, from strategy planning to study execution and BLA/NDA submissions.
Prior to his career at Seattle Genetics, Dr. Sievers was Medical Director at ZymoGenetics where he designed and supervised clinical trials of recombinant human interleukin 21 and TACI-Fc5 for patients with cancer and evaluated new oncology opportunities.
Dr. Sievers’ most recent position was Chief Medical Officer at Trillium Therapeutics where he developed clinical trial strategies and oversaw all clinical development employing a decoy receptor to block the CD47 “Do not eat” signal overexpressed by cancer cells.
BioAtla has two programs currently in Phase 1/2 clinical testing in the United States.